Genetic factors contribute to the pathogenesis of coronary artery disease (CAD). We studied 100 patients with CAD and 50 healthy individuals to assess the association of endothelial nitric oxide (eNOS) polymorphism (Glu298Asp) and angiotensinogen polymorphisms (M235T) and CAD in an Egyptian population. Serum nitric oxide (NO) and angiotensin I levels were also measured. The frequency of Glu298Asp and M235T polymorphisms were higher in the CAD group compared with controls. The mean level of NO was significantly lower (P < .05) while angiotensin I was significantly higher (P < .05) in patients CAD than in controls. The frequency of eNOS TT allele of M235T variant was significantly higher in patients with CAD (20% vs 6%). The frequency of angiotensinogen (AGT) TT and T allele in patients with CAD was significantly higher (P < .05) than in controls (22% vs 6%and 47% vs23%, respectively). Homozygosity for Glu298Asp and M235T polymorphisms may predispose to CAD.
Rabelo LMAtherosclerotic risk factors in adolescence. J Pediatr ( Rio J). 2001;77(2):s53-s64.
2.
Tesauro M., Thompson WC, Rogliani P.Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary disease: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci USA. 2000;97(6):2832-2835.
3.
Savvidou MD, Vallance PJ, Nicolaides KHEndothelial nitric oxide synthase gene polymorphism and maternal vascular adaptation to pregnancy. Hypertension. 2001 ;38(6):1289-1293.
4.
Leeson CP, Hingorani AD, Mullen MJGlu298Asp endothelial nitric oxide synthase gene polymorphism interacts with environmental and dietary factors to influence endothelial function. Circ Res. 2002;90(11):1153-1158.
5.
Davignon J., Ganz P.Role of endothelial dysfunction in atherosclerosis. Circulation . 2004;109(23 suppl 1):I1127-I1132.
6.
Hilgenfeldt U.Half-life of rat angiotensinogen: influence of nephrectomy and lipopolysaccharide stimulation. Moll Cell Endocrinol. 1988;56(1-2):91-98.
7.
Hall JEHistorical perspective of the renin-angiotensin system. Mol Biotechnol. 2003;24(1):27-39.
8.
Gluba A., Banach M., Mikhailidis DP, Rysz J.Genetic determinants of cardiovascular disease: the renin-angiotensin-aldosterone system, paraoxonases, endothelin-1, nitric oxide synthase and adrenergic receptors . In Vivo.2009;23(5):797-812.
9.
Agachan B., Isbir T., Yilmaz H., Akoglu E.Angiotensin converting enzyme I/D, angiotensinogen T174M-M235T II type 1 receptor A1166C gene polymorphism in Turkish hypertensive patients. Exp Mol Med. 2003;35(6):545-549.
10.
Goldman L., Hashimoto B., Cook EF, Loscalzo A.Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation. 1981;64(6):1227-1234.
11.
Colombo MG, Andreassi MG, Paradossi U., et al. Evidence for association of a common variant of the endothelial nitric oxide synthase gene (Glu298→Asp polymorphism) to the presence, extent and severity of coronary artery disease. Heart. 2002; 87(6):525-528.
12.
Yoshimura M. , Yasue H., Nakayama M., et al. A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum Genet. 1998;103(1):65-69.
13.
Chang K., Baek SH, Seung KB, et al. The Glu298Asp polymorphism in the endothelial nitric oxide synthase gene is strongly associated with coronary spasm. Coron Artery Dis. 2003;14(4):293-299.
14.
Kerkeni M., Addad F., Chauffert M., et al. Hyperhomocysteinemia, endothelial nitric oxide synthase polymorphism, and risk of coronary artery disease. Clin Chem. 2006;52(1):53-58.
15.
Wang CL, Hsu LA, Ko YS, Ko YL, Lee YHLack of association between the Glu298Asp variant of the endothelial nitric oxide synthase gene and risk of coronary artery disease among Taiwanese. J Formos Med Assoc. 2001;100(11):736-740.
16.
Schmoelzer I., Renner W., Paulweber B., et al. Lack of association between the Glu298Asp polymorphism of the endothelial nitric oxide synthase with manifest coronary artery disease, carotid atherosclerosis and forearm vascular reactivity in two Austrian populations. Eur J Clin Invest. 2003;33(3):191-198.
17.
Afrasyap L. , Ozturk G.NO level and endothelial NO synthase gene polymorphism (Glu298Asp) in the patients with coronary artery disease from the Turkish population. Acta Biochemica Biophisica Sinica . 2004;36(10):661-666.
18.
Arora S., Nibhriti Das N., Srivastava K.Nitric oxide and eNOS gene in essential hypertension. Intern J Collaborative Res Internal Med Public Health. 2009;1(2):56-71.
19.
Yoon Y., Song J., Hong SH, Kim JQPlasma nitric oxide concentrations and nitric oxide synthase gene polymorphisms in coronary artery disease. Clin Chem. 2000 ;46(10):1626-1630.
20.
Hingorani AD , Liang CF, Fatibene J.A common variant of the endothelial nitric oxide synthase (Glu298→Asp) is a major risk factor for coronary artery disease in the UK. Circulation. 1999; 100(14):1515-1520.
21.
Stuehr DJStructure-function aspects in the nitric oxide synthases. Annu Rev Pharmacol Toxicol. 1997;37:339-359.
22.
Gardemann A. , Lohre J., Cayci S. The T allele of the missense Glu298Asp endothelial nitric oxide synthase gene polymorphism is associated with coronary heart disease in younger individuals with high atherosclerotic risk profile . Atherosclerosis. 2002; 160(1):167-175.
23.
Kuo LT, Wang CH, Yang NI, et al. Relation between M235T polymorphism of the angiotensinogen gene and coronary artery disease in Taiwanese: an angiography-controlled study . Acta Car-diol Sin. 2008;24:75-79.
24.
Jeunemaitre X., Soubrier F., Kotelevtsev YV, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell. 1992; 71(1):169-180.
25.
Fernández-Arcás N., Dieguez-Lucena JL, Muñoz-Morán E., et al. Both alleles of the M235T polymorphism of the angiotensinogen gene can be a risk factor for myocardial infarction. Clin. Genet . 2001;60(1):52-57.
26.
Goldenberg I., Moss AJ, Ryan D., McNitt S., Eberly SW, Zareba W.Polymorphism in the angiotensinogen gene, hypertension, and ethnic differences in the risk of recurrent coronary events . Hypertension. 2006;48(4):693-699.
27.
Staessen JA , Kuznetsova T., Wang JG, Emelianov D., Vlietinck R., Fagard R.M235T angiotensinogen gene polymorphism and cardiovascular renal risk. J Hypertens. 1999 ;17(1):9-17.
28.
Ozisik K., Misirlioglu M., Ulus TA, Tuncer S., Emir M., Katircioglu F.Renin-angiotensin system polymorphisms and coronary artery surgery patients . Asian Cardiovasc Thorac Ann. 2005;13(2):153-156.
29.
Buraczynska M., Pijanowski Z., Spasiewicz D., et al. Renin-angiotensin system gene polymorphisms: assessment of the risk of coronary heart disease. Kardiol-Pol . 2003;58(1):1-9.
30.
Lanz JR, Pereira AC, Lemos PA, Martinez E., Krieger JEAngiotensinogen M235T polymorphism is associated with coronary artery disease severity. Clin Chim Acta. 2005;362(1-2):176-181.
